Jan Bogaerts earned his degree in mathematics (1986) and his PhD in mathematics (1993) at the Free University of Brussels (Belgium). In 1988 he also earned a degree in management at the Free University in Brussels.
He joined BMS in 1993 as statistician. Later, as Associate Director Statistics he worked on several drugs in oncology, including several FDA and EMEA submissions.
In 2004 he joined the EORTC as statistician of the EORTC Breast Cancer Group. He now has the role of Methodology Director. He contributed to the development of RECIST and is on the RECIST Steering Committee. Another key role of his is statistician of the MINDACT trial EORTC 10041 – BIG 3-04 (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy: A prospective, randomized study comparing the 70-gene signature with the common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes) which will soon report primary results.
Current statistical interests include the use of and methodological issues around Progression Free Survival, alternative ways to use changes in tumor measurements as predictive markers, and the correct evaluation of the contribution of new markers to existing prognostic risk evaluation. He also has a high interest in closing the gap between clinical trials and day-to-day practice, and in increasing scientific learning from merging multiple data sources.